Journal of Cancer Research and Clinical Oncology

, Volume 137, Issue 8, pp 1255–1262 | Cite as

Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population

  • M. Moshahid Alam RizviEmail author
  • M. Shabbir Alam
  • Asgar Ali
  • Syed Jafar Mehdi
  • Swaraj Batra
  • A. K. Mandal
Original Paper



PTEN, a tumor-suppressor gene located on chromosome 10q23.3 is implicated in multiple tumors including cervical carcinoma.


We examined 135 cervical cancer specimens for PTEN gene expression and promoter methylation using methylation-specific PCR and immunohistochemistry and also studied the mutation in PTEN gene through PCR-single-stranded conformational polymorphism. PTEN expression and its methylation status were also correlated with clinicopathologic parameters.


The results showed an abnormal band on exon 5 and exon 9 of the PTEN gene. In PTEN gene, 61% specimen showed methylation. PTEN methylation was found in 39% cases of stage I, 60% of stage II, and 75% of stages III–IV. The correlation between PTEN methylation and clinical stage was found to be statistically significant (P = 0.003). Nuclear PTEN expression was detected in 84 of 135 (62%) cases of cervical carcinoma, and the remaining 51 of 135 (38%) cases were observed as expressional loss. The loss of PTEN expression was significantly correlated clinical stage (P = 0.001). Loss of PTEN expression was observed in 34 (41%) cases among 83 methylation positive cases, whereas among 52 methylation-negative cases, only 13 (25%) cases were seen as immunostaining negative with the statistically significant value (P = 0.05).


Promoter methylation and loss of PTEN expression occur frequently in carcinoma of uterine cervix. Our results suggest that PTEN plays an important role in the carcinogenesis of cervical cancer.


PTEN Cervical cancer Methylation Immunohistochemistry 



The authors acknowledge University Grants Commission (UGC), Government of India, New Delhi, for providing the fund for this study. The authors also acknowledge Mr. M. Irshad and Mr. Irfan Ahmad for their valuable suggestions during the manuscript preparations.

Conflict of interest



  1. Alam MS, Rizvi MM (2011) Cancer of the uterine cervix and PTEN tumor suppressor gene. Lambert Academic Publishing, GermanyGoogle Scholar
  2. American Cancer Society (2009) Cancer facts & figures. American Cancer Society, AtlantaGoogle Scholar
  3. Aneta JJ, Bożena K, Cyprian G, Urszula N (2010) TP53 Mutations in Endometrial Cancers: Relation to PTEN Gene Defects. Int J Gynecol Cancer 20(2):196–202CrossRefGoogle Scholar
  4. Benedet JL, Bender H, Jones H III, Ngan HYS, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 70:209–262CrossRefGoogle Scholar
  5. Cheung TH, Lo WK, Yim SF, Chan LK, Jeung MS, Chan CS, Cheung A, Chung TK, Wong YF (2004) Epigenetic and genetic alteration of PTEN in cervical neoplasm. Gynecol Oncol 93:621–627PubMedCrossRefGoogle Scholar
  6. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. In: IARC Cancer base No. 5, version 2.0. IARC Press, LyonGoogle Scholar
  7. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK (1995) Loss of the chromosomal region 10q23–25 in prostate cancer. Cancer Res 55:4800–4803PubMedGoogle Scholar
  8. Guldberg P, Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57:3660–3663PubMedGoogle Scholar
  9. Guo CY, Xu XF, Wu JY, Liu SF (2008) PCR-SSCP-DNA sequencing mrthod in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol 14(24):3804–3811PubMedCrossRefGoogle Scholar
  10. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 93:9821–9826PubMedCrossRefGoogle Scholar
  11. Huang J, Kontos CD (2002) PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 277:10760–10766PubMedCrossRefGoogle Scholar
  12. Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D, Balcerska A, Klepacka T, Limon J (2010) EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours. Folia Neuropathol 48(4):238–245PubMedGoogle Scholar
  13. Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N (2002) Activation of Akt/protein kinase B overcomes a G (2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22:7831–7841PubMedCrossRefGoogle Scholar
  14. Kang YH, Lee HS, Kim WH (2002) Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 82:285–291PubMedGoogle Scholar
  15. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S et al (1997) PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17:143–144PubMedCrossRefGoogle Scholar
  16. Lazo PA (1999) The molecular genetics of cervical carcinoma. Br J Cancer 80:2008–2018PubMedCrossRefGoogle Scholar
  17. Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947PubMedCrossRefGoogle Scholar
  18. McConnachie G, Pass I, Walker SM, Downes CP (2003) Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. Biochem J 371(3):947–955PubMedCrossRefGoogle Scholar
  19. Mitra AB, Murty VS, Li RG, Pratap M, Luthra UK, Chaganti SK (1994) Allelotype analysis of cervical carcinoma. Cancer Res 54:4481–4487PubMedGoogle Scholar
  20. National Cancer Registry Programme (2007) Consolidated report of hospital based cancer registries 2001–2003. ICMR, New DelhiGoogle Scholar
  21. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  22. Preacher KJ (2001) Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. Available from
  23. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57:4187–4190PubMedGoogle Scholar
  24. Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102:678–684PubMedCrossRefGoogle Scholar
  25. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J (1997) Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57:3657–3659PubMedGoogle Scholar
  26. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, Das S (2001) PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91:22–26PubMedCrossRefGoogle Scholar
  27. Sambrook J, Russell DW (2001) Molecular Cloning: A Laboratory Manual, 3rd edn. Cold Spring Harbor Lab. Press, plainviewGoogle Scholar
  28. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri F (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8:1178–1184PubMedGoogle Scholar
  29. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29–39PubMedCrossRefGoogle Scholar
  30. Steck PA, Pershouse MA, Jasser SA et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362PubMedCrossRefGoogle Scholar
  31. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRefGoogle Scholar
  32. Wang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95:5246–5250CrossRefGoogle Scholar
  33. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95:15587–15591PubMedCrossRefGoogle Scholar
  34. Yang HJ, Liu SW, Wang Y, Tsang CK, Ngan YS (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinic-pathological data. BMC Cancer 6:212PubMedCrossRefGoogle Scholar
  35. Zhang L, Liu T, Liu H, Gao J, Gu C (2000) Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer. Zhonghua Bing Li Xue Za Zhi 29:85–88PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. Moshahid Alam Rizvi
    • 1
    Email author
  • M. Shabbir Alam
    • 1
    • 2
  • Asgar Ali
    • 1
  • Syed Jafar Mehdi
    • 1
  • Swaraj Batra
    • 3
  • A. K. Mandal
    • 4
  1. 1.Genome Biology Lab, Department of BiosciencesJamia Millia Islamia, Maulana Mohammad Ali Jauhar MargNew DelhiIndia
  2. 2.Department of Medical Lab Technology, Faculty of Applied Medical SciencesJazan UniversityJizanKingdom of Saudi Arabia
  3. 3.Department of Obstetrics & GynecologyLNJP/MAMC CampusNew DelhiIndia
  4. 4.Department of PathologyMAMC CampusNew DelhiIndia

Personalised recommendations